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Abstract: In this study a series of curcumin analogues were evaluated for their ability to 
inhibit the activation of NF-κΒ, a transcription factor at the crossroads of cancer-inflammation. 
Our novel curcumin analogue BAT3 was identified to be the most potent NF-κB inhibitor 
and EMSA assays clearly showed inhibition of NF-κB/DNA-binding in the presence of 
BAT3, in agreement with reporter gene results. Immunofluorescence experiments 
demonstrated that BAT3 did not seem to prevent nuclear p65 translocation, so our novel 
analogue may interfere with NF-κB/DNA-binding or transactivation, independently of 
IKK2 regulation and NF-κB-translocation. Gene expression studies on endogenous NF-κB 
target genes revealed that BAT3 significantly inhibited TNF-dependent transcription of 
IL6, MCP1 and A20 genes, whereas an NF-κB independent target gene heme oxygenase-1 
remained unaffected. In conclusion, we demonstrate that BAT3 seems to inhibit different 
cancer-related inflammatory targets in the NF-κB signaling pathway through a different 
mechanism in comparison to similar analogues, previously reported. 
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1. Introduction 
In 1863, Rudolf Virchow was the first who made a connection between inflammation and cancer as 
he noticed the appearance of leucocytes in neoplastic tissues. Cancer is a multi-step disease [1] that 
affects people worldwide [2], and now it is well-established that is closely related to inflammation [3–9]. 
Various inflammatory mediators, such as chemokines and cytokines, are present in tumor cells, while 
targeting these, may provide new approaches for cancer therapy [10]. Cancer cells and tumor-associated 
immune cells contain multiple hyperactivated signal transduction pathways due to their transformation. 
Often they are activated following exposure to established cytotoxic therapies including ionizing 
radiation and chemical agents that cause DNA damage. Many pathways, activated in response to 
transformation or toxic stress, promote cell growth, invasion and prevent the processes of cell death. 
As a result of these findings, many drugs with varying specificities have been developed to block 
signaling by cell survival pathways in the hope of killing tumor cells and sensitizing them to toxic 
therapies [11]. Unfortunately, due to the plasticity of signaling processes, inhibition of any growth 
factor receptor or pathway has modest long-term effects on cell viability, tumor growth, and patient 
survival. As such the concept of multi-target treatment holds promise for cancer treatment or 
prevention [12–14]. As a result of this observation, there has been a growing interest in multifocal 
natural compounds, such as polyphenols, withanolides, xanthones, indanones, curcuminoids, which 
simultaneously inhibit multiple inter-linked signal transduction/survival pathways [11,15–20]. The 
past decades, researchers searching for new drugs to use in oncology have refocused on natural 
products [21,22]. 
A key player at the crossroad of cancer and inflammation is the transcription factor NF-κB, which is 
deregulated in various inflammatory diseases and cancer [6,23,24]. For example, NF-κB activity is 
strongly increased in estrogen receptor-negative, p53-mutated breast cancer cells such as  
MDA-MB231 [25–27]. NF-κB-regulated genes are involved in invasiveness, proliferation, angiogenesis, 
metastasis and inflammation. In cancer, Νuclear Factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) is frequently autoactivated upon autocrine/paracrine production of pro-inflammatory 
cytokines and growth factors (i.e., TNF, EGF) [28,29]. In the “classic” NF-κB activation pathway, the 
heterodimer p50/p65 is inactive in the cytoplasm through its association with IκBα protein. After 
cellular activation by TNF (Tumor Necrosis Factor), IκBα is phosphorylated at two serine residues 
(Ser 32, Ser 36) by the IKK complex, containing the IκB kinases (IKKs): IKKα (also known as IKK1), 
IKKβ (also known as IKK2) and a non-catalytic regulatory subunit (NEMO/IKKγ) [30]. Activation of 
the IKK complex requires phosphorylation of two serine residues located in the “activation loop” 
within the kinase domain of at least one of the catalytic IKK subunits. The activated IKK complex 
phosphorylates in turn IκBα, causing its degradation by the proteasome and allowing free p50/p65 
subunit to translocate into the nucleus in order to bind to κB sites in the promoter of several genes and 
to activate transcription. Besides regulation of NF-κB/DNA binding, additional pathways are involved in 
gene-specific NF-κB transactivation mechanisms depending on the epigenetic marks and cofactor 
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repertoire recruited to the various NF-κB target sequences [31–35]. As such, various therapeutic 
strategies aim to decrease chronic hyperactivated NF-κB by pharmacological as well as 
phytomedicinal approaches [16,30,36–43]. 
Today, epidemiological and clinical studies with curcumin, a principal component of turmeric  
(a curry spice) showing strong pleiotropic anti-oxidant and anti-inflammatory activities and an 
excellent safety profile, reveal promising anti-cancer effects at the molecular level in vitro as well as in 
vivo. However, effects to prevent or reduce cancer so far did not achieve its optimum therapeutic 
outcome in past clinical trials, largely due to its low solubility and poor bioavailability [44,45]. As 
such, curcumin analogues with improved pharmacokinetic properties may enable its enhanced 
absorption and cellular uptake. 
Curcumin or diferuloylmethane (Figure 1) is a polyphenolic yellow colored natural derivative, 
isolated from the dried rhizome of the herb Curcuma longa Linn (turmeric). It is a multi-target agent 
that interacts with multiple targets in the NF-κB signaling pathway implicated in cancer and  
inflammation [45–50]. Curcumin suppresses the activation of IKK, the phosphorylation and 
degradation of IκBα, nuclear translocation of the p65 subunit in several cancer cell lines as well as 
inhibition of the proteasome function [51–58]. Various curcumin analogues are also known to inhibit 
the NF-κB signal transduction pathway [59,60].  
 
 
Figure 1. Chemical structures of curcumin and monoketone analogues of curcumin. 
Recently we have published a series of curcumin analogues as anti-inflammatory and anti-proliferative 
agents. Among them analogue BAT3 presented interesting anti-proliferative activity with GI50 3.3 uM 
in SF268 (Central Nervous System, glioma) cancer cell line [61]. Similarly, monoketone analogues of 
curcumin, EF24 and EF31 (Figure 1) show improved NF-κB inhibition, by attenuating the catalytic 
activity of IKK and blocking the nuclear translocation of NF-κB [62,63]. PAC (Figure 1) triggered 
apoptosis and inhibited several breast cancer-related proteins, among which NF-κΒ and its downstream 
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effectors, such as cyclin D1 and Bcl-2 [64]. In addition, Yadav et al.; synthesized a series of heterocyclic 
cyclohexanone analogues of curcumin, which were examined for the ability to inhibit NF-κB 
transactivation in non-adherent K562 leukemia cells. Among these, the three analogues B1, B10 and 
C1 (Figure 1), showed potent cytotoxicity and inhibition of NF-κB activation [65]. In the present 
paper, we will evaluate the anti-inflammatory potencies of a series of novel curcumin analogues 
(Figure 2) [61], by means of NF-κB reporter gene assays, mRNA transcription analysis, NF-κB 
immunofluorescence microscopy and NF-κB/DNA binding studies. 
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Figure 2. Chemical structures of the curcumin analogues investigated.  
2. Results and Discussion 
2.1. Structure-Function Analysis of Anti-Inflammatory Activity of Curcumin Analogues by Means of 
NF-κB Reporter Gene Screening 
In order to investigate the potential NF-κB immunosuppressive effects of the various curcumin 
analogues, we performed dose response experiments in L929sA fibroblasts stably transfected with the 
recombinant NF-κB dependent reporter gene construct, p(IL6κB)350hu.IL6P-Luc+, containing multiple 
NF-κB-responsive elements in front of a minimal IL-6 promoter, coupled to the luciferase reporter 
gene. Enhanced luciferase expression levels can be measured in response to TNF, as compared to the 
untreated setup, indicating that the cellular TNF response towards NF-κB activation is functional. 
Upon pretreatment with the various compounds, a significant dose-dependent inhibition of NF-κB 
reporter gene expression could be observed with analogues BAT1, 3 and 8. BAT3, reveals the most 
potent NF-κB inhibition (Figure 3) with an approximate IC50 value of 6 µM, as compared to 15 µM for 
BAT8 and 24 µM for BAT1 (Table 1). Dexamethasone (DEX) and withaferin A (WA) were included 
as reference immunosuppressive compounds [19,66]. NF-κB-specific promoter effects are normalized 
against the constitutive promoter activity of the co-transfected PGK reporter gene plasmid. 
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Figure 3. BAT3 inhibits NF-κB-driven reporter gene expression. L929sA cells stably 
transfected with p(IL6κB)350hu.IL6P-Luc and PGK-Gal were left untreated (untr) or were 
treated with 2000 IU/mL TNF for 4 h either alone or following a 24 h pretreatment with 
different doses of BAT3. Lysates were prepared for quantification of luciferase reporter 
gene expression levels and correction for potential cytotoxicity by evaluating corresponding 
constitutively expressed galactosidase levels. The relative induction factor is defined as the 
amount of luciferase produced in TNF-treated cells after normalization for galactosidase 
expression compared with the non-induced state. Statistical significant repression by BAT3 
is indicated as ** p < 0.01 or *** p < 0.001.  
Table 1. IC50 values of examined compounds. 
Compounds IC50 (µM) 
BAT1 24 
BAT2 inactive 
BAT3 6.5 
BAT4 inactive 
BAT5 inactive 
BAT7 inactive 
BAT8 15 
BAT13 inactive 
2.2. Effect of the BAT3 Compound on NF-κB Activation, Translocation and NF-κΒ/DNA Binding 
Furthermore, upon immunofluorescent detection of subcellular pools of NF-κB p65 in cells treated 
with TNF alone or following combination treatment with BAT3, we could clearly detect TNF-induced 
translocation of NF-κB p65 from the cytoplasm to the nucleus (Figure 4). Remarkably, BAT3 fails to 
block NF-κB translocation, since NF-κB p65 staining remains predominantly nuclear (Figure 4A–C). 
Also, since various NF-κB inhibitors sensitize for TNF incuded cell death, combination treatment of 
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TNF + BAT3 also revealed mild cytotoxic effects in immunofluorescence images [67,68]. Altogether, 
this suggests that NF-κB inhibition by BAT3 cannot be explained by blocking TNF induced p65  
nuclear translocation. 
  
 
Figure 4. BAT3 does not inhibit nuclear NF-κB translocation. (A) A549 cells grown on 
coverslips were incubated with 25 µM BAT3 for 2 h and then stimulated with 2000 IU/mL 
TNF for 30 min. After cell fixation, nuclei were visualized by blue DAPI staining and 
nuclear translocation of NF-κB was monitored by overlay of blue DAPI staining with anti-p65 
green immunofluorescence microscopy; (B) Close-ups of NF-κB p65 immunofluorescence 
intensities across cytoplasmic and nuclear cell compartments for the difffeent treatments;  
(C) Cross-cellular (yellow line) fluorescence intensity plots were determined by Image J 
software (National Institutes of Health, Bethesda, MD, USA, version 1.49c, 2014) for the 
different treatments. For control and BAT3 treated cells, p65 immunofluorescence can be 
observed predominantly in the cytoplasm, with a relative lower fluorescence intensity 
across the nuclear region as expected. However, upon evaluating immunofluorescence 
signals following TNF or combined TNF + BAT3 treatment, p65 signal intensity is shifted 
more exclusively towards the nucleus as compared to the intensities observed in the 
cytoplasmic periphery. 
A 
B C 
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Next, we evaluated whether the inhibition of NF-κB reporter gene activity by BAT3 occurs at the 
level of NF-κB/DNA-binding. Following cellular fractionation [69], we measured TNF-induced  
NF-κB/DNA binding levels in EMSA following 30 min TNF treatment, either alone or following 2 h 
pretreatment with BAT3 in L929 fibrosarcoma and A549 lung epithelial cells (Figure 5). As expected, 
TNF stimulation induces a significant increase in NF-κB/DNA binding. Interestingly, a 2 h 
pretreatment of cells with BAT3 prevents basal and/or TNF-induced NF-κB/DNA binding. Of special 
note, the binding levels of a constitutive nuclear recombination signal sequence-binding protein Jκ 
(RBP-Jκ), binding to the same NF-κB DNA motif remain unaffected under all conditions tested, 
pointing to a specific inhibition of nuclear NF-κB/DNA binding [69]. These results are in line with the 
reporter gene results. 
 
Figure 5. BAT3 inhibits NF-κB/DNA binding, L929sA and A549 cells were incubated 
with 25 µM BAT3 for 2 h and then stimulated with 2000 IU/mL TNF for 30 min. 
Corresponding nuclear lysates were incubated with a 32P-labeled IL-6κB site-containing 
probe and analyzed for NF-κB/DNA-binding complexes in EMSA. Loading of equal 
amounts of nuclear protein was verified by comparison with the constitutive binding 
activity of the repressor molecule recombination signal sequence-binding protein Jκ  
(RBP-Jκ). Black arrows indicate NF-κB binding complexes p50–p65 and p50–p50. 
2.3. Transcriptional Effect of the BAT3 Compound on Endogenous NF-κB Target Genes 
Next, NF-κB-suppressive effects of the BAT3 compound were validated by real-time QPCR on the 
expression of different NF-κB target genes involved in inflammation and prevention of apoptosis. The 
relative amount of target mRNA was determined using the comparative threshold (Ct) method by 
normalizing target mRNA Ct values to those for β-actin. The results show that compound BAT3 
significantly downregulates the expression of various TNF inducible NF-κB target genes such as IL-6, 
MCP1 and A20. Surprisingly, another TNF inducible NF-κB target gene COX2 remains unaffected  
Molecules 2015, 20 870 
 
 
in presence of BAT3. Also, the constitutively expressed target gene Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), which does not contain an NF-κB binding motif in its promoter 
and as such does not respond to TNF, remains unaffected by BAT3 treatment (Figure 6). Of special 
note, in contrast to general inhibition of NF-κB/DNA binding by BAT3 observed in synthetic 
reportergene (Figure 3) and in vitro in vitro EMSA DNA-binding studies (Figure 5), evaluation of 
BAT3 effects at endogenous NF-κB target genes reveals a more selective mechanism of NF-κB 
inhibition. Indeed, combinatorial control of transcription factor binding and chromatin dynamics by 
posttranslational modifications may further contribute in selective nuclear regulation of NF-κB-target 
genes by BAT3 [31,70]. Along the same line, we have previously demonstrated selective inhibition of 
endogenous NF-κB target genes by MSK1 and MAPK inhibitors via coregulation of transcription 
factor and chromatin histone marks [35,71]. As such our results suggest that BAT3 may interfere more 
selectively with NF-κB dependent gene expression at the chromatin-DNA interface. In line with our 
hypothesis, various reports have recently demonstrated significant effects of curcumin analogues on 
histone acetylation of inflammatory genes [72,73]. Whether curcumin analogues may interfere with 
MSK1 regulation of NF-κB-chromatin marks needs further investigation. 
 
Figure 6. BAT3 inhibits endogenous NF-κB target gene expression. L929sA cells left 
untreated or treated with 25 µM BAT3 for 2 h were subsequently stimulated with 2000 IU/mL 
TNF for 3 h. Total cytoplasmic RNA was isolated, and converted to cDNA. Corresponding 
gene expression levels of TNF inducible genes IL6, IL8, A20, COX2 and the constitutively 
transcribed HPRT (Hypoxanthine-guanine phosphoribosyltransferase 1) were evaluated by 
Sybr green Q-PCR analysis and were normalized for gene expression of the housekeeping 
gene β-actin. Statistical significant repression by BAT3 is indicated as not significant  
ns p > 0.05, * p < 0.05, ** p < 0.01 or *** p < 0.001.  
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3. Experimental Section 
3.1. Compounds, Cytokine and Reagents 
The curcumin analogues BAT (Figure 2) were prepared as previously described [61]. Withaferin A 
was purchased from Chromadex (Irvine, CA, USA) and dexamethasone (DEX) was obtained from  
Sigma-Aldrich (St. Louis, MO, USA). Compounds were stored as 10 mM solutions in DMSO at −20 °C. 
A549 cells were purchased from ATCC. Recombinant murine TNF, produced in Escherichia coli and 
purified to at least 99% homogeneity, had a specific biological activity of 8.58 × 107 IU/mL of protein 
as determined in a standard TNF cytolysis assay [35]. Reference TNF (code 88/532) was obtained 
from the National Institute of Biological Standards and Control (Potters Bar, UK). 
3.2. Transfection Procedure—Cell Cultures 
The murine fibrosarcoma L929A cells, stably transfected with the recombinant NF-κB-driven 
reporter gene construct p(IL6κB)350hu.IL6P-Luc+ and co-transfected with the reference reporter 
plasmid PGK-neogalactosidase, which constitutively expresses a neomycin resistance protein fused to 
a galactosidase reporter protein controlled by the housekeeping promoter phosphoglycerate kinase 
(PGK), were previously described [33,35]. L929sA and A549 (human lung epithelial) cells were grown 
at 37 °C, 95%–98% humidity and 5% CO2 incubator in Dulbecco Modified Eagle’s Medium (DMEM) 
(Gibco, Invitrogen, Carlsbad, CA, USA), supplied with 5% fetal calf serum, 5% Newborn calf serum 
(Greiner bio-one, Frickenhausen, Germany), 0.2% of P/S antibiotic (100 U/mL penicillin, 0.1 mg/mL 
streptomycin) (Gibco, Invitrogen) and 10% glutamine 2 mM. 
3.3. Treatment—Cell Lysis 
Twenty four hours before treatment with the compounds, L929 cells were seeded in 96-well plates 
such that they were confluent at the time of the experiment. After cells were treated with the 
compounds overnight, cells were left untreated or treated with 2500 U/mL TNF for 4 h. After the 
indicated induction time, medium supernatant was removed, the cells were washed with ice-cold 
PBSA and lysed in reporter lysis buffer (Promega Biotec, Madison, WI, USA). 
3.4. Reporter Gene Analysis 
Analysis—Luciferase assays were carried out according to the instructions of the manufacturer 
(Promega Biotec) and have been described previously [35]. Light emission was measured in a 
luminescence microplate counter (Top-Count; Packard Instrument Co., Meriden, CT, USA). Normalization 
of luciferase activity, expressed in arbitrary light units, was performed by measurement of β-galactosidase 
levels in a chemiluminescent reporter assay Galacto-Light kit (Tropix, Bedford, MA, USA). 
3.5. Immunofluorescence Microscopy 
Lung epithelial cells (A549) were seeded on coverslips and starved in phenol red- and serum-free 
medium for 24 h before starting treatment with the compounds and inductions. Cells were pretreated 
with the compounds of interest (25 μM) for 2 h, followed by TNF induction for 30 min. The cells were 
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fixed in 4% formaldehyde in phosphate-buffered saline (PBS), permeabilized with ice cold aceton for  
3 min, and then blocked in 5% milk–10% FCS–0.3% bovine serum albumin–0.3% Triton X-100 in 
PBS for 1 h at room temperature. P65 was visualized by using a 1:200 dilution of the anti-p65 antibody 
overnight (NF-κB p65 (C20) rabbit polyclonal 200 µg/mL Santa Cruz Biotechnology (Santa Cruz, CA, 
USA), followed by probing with a 1:800 dilution of Alexa Fluor 488 donkey anti rabbit IgG (H+L)  
2 mg/mL (Invitrogen, Carlsbad, CA, USA). Cell nuclei were visualized by DAPI staining. Samples 
were analyzed by a Zeiss axiovert 200 using AxioVision Rel.4.5 software (Carl Zeiss, Jena, Germany). 
Densitometric line plot profiles of immunofluorescencen intensities across cytoplasmic and nuclear 
cell regions were determined by ImageJ freeware (National Institute of Health, Bethesda, MD, USA). 
3.6. Electrophoretic Mobility Shift Assay (EMSA) 
L929sA and A549 were seeded in 6-well plates at 3 × 105 cells/well and treated 2 h with the 
compound of interest (25 μM) and 30 min with or without TNF. After treatment, cells were washed 
with ice-cold PBS and pelleted in 1 mL PBS by centrifugation for 10 min at 2600 rpm (4 °C). 
Preparation of nuclear extracts has been described previously [69]. For EMSA, equal amounts of protein 
were incubated for 25 min with an NF-κB-specific 32P-labeled oligonucleotide and binding mix as 
described previously [19]. For supershift assay, antibodies were preincubated to the sample of interest 
for 10 min prior to incubation with radiolabeled probe [69]. Labeling of the oligonucleotides was 
performed with [α-32P]-dCTP by using Klenow enzyme (Boehringer, Mannheim, Germany). For EMSA 
competition assays, 100 fold excess of unlabeled NF-κB oligonucleotide was added to the binding mix. 
The NF-κB oligonucleotide comprises the sequence: 5'-AGCTATGTGGGTTTTCCCATGAGC-3', in 
which the single IL6 promoter-derived NF-κB motif is underlined. Samples were loaded on a 6% 
polyacrylamide gel run in 0.5× TBE buffer (pH 8) and complexes formed were analyzed using 
Phosphor Imager Technology [74]. 
3.7. RNA Isolation and Real-Time Q-PCR Analysis 
Murine fibrosarcoma L929A were seeded in 6-well plates 24 h before treatment with the 
compounds, such that they were confluent at the time of the experiment. Cells were pretreated with the 
compounds of interest (25 μM) for 2 h, followed by TNF induction for 3 h. Total RNA was extracted 
with TRIzol (Invitrogen, Merelbeke, Belgium), as described by the manufacturer. The quality and the 
quantity of the RNA were measured by Nanodrop equipment (Thermo Fisher Scientific, Waltham, 
MA, USA). Concentrations of samples were determined and 500 ng RNA was used in a RT-step with 
MMLV reverse transcriptase (Promega, Madison, WI, USA) to produce the respective cDNA. Briefly 
an aliquot of 500 ng of RNA sample, 1 μL oligo (dT) (Promega), 10 μL MMLV buffer 5× (Promega), 5 μL 
2.5 mM dNTP mix, 0.5 μL RNasin®, 1 μL mMLV reverse transcriptase (Promega) were mixed and 
adjusted to a final volume of  50 μL by DEPC-H2O in a PCR tube, and the reverse transcription 
reaction was conducted using the following conditions: 60 min at 42 °C, 15 min at 75 °C, and 30 min 
at 4 °C in a PCR machine (Perkin Elmer, Waltham, MA, USA). 
The Q-RT-PCR was performed using Invitrogen Sybr green platinum Supermix-UDG on a iCycler 
apparatus (Bio-Rad, Eke, Belgium). The obtained cDNA was diluted 5 times before use. Briefly 7.5 μL 
SYBR Green master mix, 0.75 μL FW primer (5 μM, diluted in baxter H2O), 0.75 μL RV primer  
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(5 μM, diluted in Baxter H2O) and 1 μL QPCR- H2O (Baxter H2O) were added to 5 μL of the diluted 
cDNA in a Q-PCR plate. Primer specificity was verified by melting curve analysis. Primer efficiencies 
were analyzed by amplification of a cDNA standard dilution. All amplifications were performed in 
triplicate and data were analyzed using Genex software (Bio-Rad). β-actin was used as housekeeping 
gene for normalization of the various target genes. Results are expressed as relative gene expression, 
i.e., N-fold differences in target gene expression relative to the β-actin gene, were determined as  
N target = 2ΔCt sample, where the ΔCt (cycle threshold) value of the sample was determined by subtracting 
the average Ct value of the target gene from the average Ct value of β-actin gene (primer efficiency of 
100%). Q-PCR primers are summarized in Table 2. 
Table 2. Primers sequences used in the real-time Q-PCR (FW: forward; RV: reverse). 
Primers Sequence 
IL6 FW GTCCTTCCTACCCCAATTTCC 
IL6 RV TTGGTCCTTAGCCACTCCTTC 
A20 FW AACCAATGGTGATGGAAACTG 
A20 RV GTTGTCCCATTCGTCATTCC 
HO1 FW AAGACCGCCTTCCTGCTCAAC 
HO1 RV CGAAGTGACGCCATCTGTGAGG 
COX2 FW TGTGCAAGATCCACAGCCTA 
COX2 RV TCTGGAGTGGGAGGCACTT 
β-actin FW CTTCTAGGCGGACTGTTACTGA 
β-actin RV CCATGCCAATGTTGTCTCTTAT 
MCP1 FW TCC CTG GTC CAA AGG TTT TTC 
MCP1 RV CTT GGT TTC CCC ATT GGA TCT 
HPRT1 FW CCTAAGATGAGCGCAAGTTGAA 
HPRT1 RV CCACAGGACTAGAACACCTGCTAA 
3.8. Statistical Analysis 
Statistics were performed using one way anova followed by Dunnett’s post-test and unpaired 
student t-test using Graph Pad Prism5 software. 
4. Conclusions 
Previous reports have shown that curcumin analogues inhibit NF-κΒ transcriptional activity by 
blocking general activation and nuclear translocation of NF-κB [62,63]. Interestingly, our results 
reveal that the novel analogue BAT3 selectively inhibits ΝF-κΒ-dependent gene expression, most 
presumably through gene specific effects of NF-κB binding to chromatin-DNA [33,35,71]. Altogether 
we demonstrate that the BAT3 curcumin analogue holds promise to selectively suppress the NF-κB 
signaling pathway. As such, genomewide investigation of BAT3 effects at the NF-κB-chromatin 
interface by chromatin immunoprecipitation sequencing experiments in different cell types may further 
corroborate its selective immunomodulatory properties in cancer-inflammation. Finally, in vivo studies 
with BAT3 are required to further evaluate its bioavailability and therapeutic efficacy, as well as 
potential improvement of its pharmacokinetic properties in comparison to curcumin. 
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